About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Viral Vaccines Market Size & Trends By 2033
Viral Vaccines Market

Viral Vaccines Market Size, Share & Trends Analysis Report By Type (Preventive Vaccine, Therapeutic Viral), By Indication (Influenza, Human Papillomavirus, Hepatitis, Measles/Mumps/Rubella), By Route of Administration (Intramuscular and Subcutaneous Administration, Oral Administration), By Patient Type (Pediatric, Adult), By Distribution Channel (Hospitals and Retail Pharmacies, Government Suppliers) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI1503DR
Last Updated : February 03, 2025
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Viral Vaccines Market Introduction
    2. By Types
      1. Introduction
        1. Types By Value
      2. Live attenuated vaccines
        1. By Value
      3. Inactivated vaccines
        1. By Value
      4. Sub-Unit viral vaccines
        1. By Value
    3. By Consumer groups
      1. Introduction
        1. Consumer groups By Value
      2. Pediatric
        1. By Value
      3. Adults
        1. By Value
    4. By Disease Indication
      1. Introduction
        1. Disease Indication By Value
      2. Cancer
        1. By Value
      3. Influenza
        1. By Value
      4. Human Papilloma Virus
        1. By Value
      5. Rota Virus
        1. By Value
      6. Poliomyelitis
        1. By Value
      7. Hepatitis
        1. By Value
      8. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. By Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
    1. Introduction
    2. By Types
      1. Introduction
        1. Types By Value
      2. Live attenuated vaccines
        1. By Value
      3. Inactivated vaccines
        1. By Value
      4. Sub-Unit viral vaccines
        1. By Value
    3. By Consumer groups
      1. Introduction
        1. Consumer groups By Value
      2. Pediatric
        1. By Value
      3. Adults
        1. By Value
    4. By Disease Indication
      1. Introduction
        1. Disease Indication By Value
      2. Cancer
        1. By Value
      3. Influenza
        1. By Value
      4. Human Papilloma Virus
        1. By Value
      5. Rota Virus
        1. By Value
      6. Poliomyelitis
        1. By Value
      7. Hepatitis
        1. By Value
      8. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. By Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
    6. U.S.
      1. By Types
        1. Introduction
          1. Types By Value
        2. Live attenuated vaccines
          1. By Value
        3. Inactivated vaccines
          1. By Value
        4. Sub-Unit viral vaccines
          1. By Value
      2. By Consumer groups
        1. Introduction
          1. Consumer groups By Value
        2. Pediatric
          1. By Value
        3. Adults
          1. By Value
      3. By Disease Indication
        1. Introduction
          1. Disease Indication By Value
        2. Cancer
          1. By Value
        3. Influenza
          1. By Value
        4. Human Papilloma Virus
          1. By Value
        5. Rota Virus
          1. By Value
        6. Poliomyelitis
          1. By Value
        7. Hepatitis
          1. By Value
        8. Others
          1. By Value
      4. By Route of Administration
        1. Introduction
          1. By Route of Administration By Value
        2. Parenteral
          1. By Value
        3. Oral
          1. By Value
    7. Canada
    1. Introduction
    2. By Types
      1. Introduction
        1. Types By Value
      2. Live attenuated vaccines
        1. By Value
      3. Inactivated vaccines
        1. By Value
      4. Sub-Unit viral vaccines
        1. By Value
    3. By Consumer groups
      1. Introduction
        1. Consumer groups By Value
      2. Pediatric
        1. By Value
      3. Adults
        1. By Value
    4. By Disease Indication
      1. Introduction
        1. Disease Indication By Value
      2. Cancer
        1. By Value
      3. Influenza
        1. By Value
      4. Human Papilloma Virus
        1. By Value
      5. Rota Virus
        1. By Value
      6. Poliomyelitis
        1. By Value
      7. Hepatitis
        1. By Value
      8. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. By Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
    6. U.K.
      1. By Types
        1. Introduction
          1. Types By Value
        2. Live attenuated vaccines
          1. By Value
        3. Inactivated vaccines
          1. By Value
        4. Sub-Unit viral vaccines
          1. By Value
      2. By Consumer groups
        1. Introduction
          1. Consumer groups By Value
        2. Pediatric
          1. By Value
        3. Adults
          1. By Value
      3. By Disease Indication
        1. Introduction
          1. Disease Indication By Value
        2. Cancer
          1. By Value
        3. Influenza
          1. By Value
        4. Human Papilloma Virus
          1. By Value
        5. Rota Virus
          1. By Value
        6. Poliomyelitis
          1. By Value
        7. Hepatitis
          1. By Value
        8. Others
          1. By Value
      4. By Route of Administration
        1. Introduction
          1. By Route of Administration By Value
        2. Parenteral
          1. By Value
        3. Oral
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Types
      1. Introduction
        1. Types By Value
      2. Live attenuated vaccines
        1. By Value
      3. Inactivated vaccines
        1. By Value
      4. Sub-Unit viral vaccines
        1. By Value
    3. By Consumer groups
      1. Introduction
        1. Consumer groups By Value
      2. Pediatric
        1. By Value
      3. Adults
        1. By Value
    4. By Disease Indication
      1. Introduction
        1. Disease Indication By Value
      2. Cancer
        1. By Value
      3. Influenza
        1. By Value
      4. Human Papilloma Virus
        1. By Value
      5. Rota Virus
        1. By Value
      6. Poliomyelitis
        1. By Value
      7. Hepatitis
        1. By Value
      8. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. By Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
    6. China
      1. By Types
        1. Introduction
          1. Types By Value
        2. Live attenuated vaccines
          1. By Value
        3. Inactivated vaccines
          1. By Value
        4. Sub-Unit viral vaccines
          1. By Value
      2. By Consumer groups
        1. Introduction
          1. Consumer groups By Value
        2. Pediatric
          1. By Value
        3. Adults
          1. By Value
      3. By Disease Indication
        1. Introduction
          1. Disease Indication By Value
        2. Cancer
          1. By Value
        3. Influenza
          1. By Value
        4. Human Papilloma Virus
          1. By Value
        5. Rota Virus
          1. By Value
        6. Poliomyelitis
          1. By Value
        7. Hepatitis
          1. By Value
        8. Others
          1. By Value
      4. By Route of Administration
        1. Introduction
          1. By Route of Administration By Value
        2. Parenteral
          1. By Value
        3. Oral
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Singapore
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Types
      1. Introduction
        1. Types By Value
      2. Live attenuated vaccines
        1. By Value
      3. Inactivated vaccines
        1. By Value
      4. Sub-Unit viral vaccines
        1. By Value
    3. By Consumer groups
      1. Introduction
        1. Consumer groups By Value
      2. Pediatric
        1. By Value
      3. Adults
        1. By Value
    4. By Disease Indication
      1. Introduction
        1. Disease Indication By Value
      2. Cancer
        1. By Value
      3. Influenza
        1. By Value
      4. Human Papilloma Virus
        1. By Value
      5. Rota Virus
        1. By Value
      6. Poliomyelitis
        1. By Value
      7. Hepatitis
        1. By Value
      8. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. By Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
    6. UAE
      1. By Types
        1. Introduction
          1. Types By Value
        2. Live attenuated vaccines
          1. By Value
        3. Inactivated vaccines
          1. By Value
        4. Sub-Unit viral vaccines
          1. By Value
      2. By Consumer groups
        1. Introduction
          1. Consumer groups By Value
        2. Pediatric
          1. By Value
        3. Adults
          1. By Value
      3. By Disease Indication
        1. Introduction
          1. Disease Indication By Value
        2. Cancer
          1. By Value
        3. Influenza
          1. By Value
        4. Human Papilloma Virus
          1. By Value
        5. Rota Virus
          1. By Value
        6. Poliomyelitis
          1. By Value
        7. Hepatitis
          1. By Value
        8. Others
          1. By Value
      4. By Route of Administration
        1. Introduction
          1. By Route of Administration By Value
        2. Parenteral
          1. By Value
        3. Oral
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Types
      1. Introduction
        1. Types By Value
      2. Live attenuated vaccines
        1. By Value
      3. Inactivated vaccines
        1. By Value
      4. Sub-Unit viral vaccines
        1. By Value
    3. By Consumer groups
      1. Introduction
        1. Consumer groups By Value
      2. Pediatric
        1. By Value
      3. Adults
        1. By Value
    4. By Disease Indication
      1. Introduction
        1. Disease Indication By Value
      2. Cancer
        1. By Value
      3. Influenza
        1. By Value
      4. Human Papilloma Virus
        1. By Value
      5. Rota Virus
        1. By Value
      6. Poliomyelitis
        1. By Value
      7. Hepatitis
        1. By Value
      8. Others
        1. By Value
    5. By Route of Administration
      1. Introduction
        1. By Route of Administration By Value
      2. Parenteral
        1. By Value
      3. Oral
        1. By Value
    6. Brazil
      1. By Types
        1. Introduction
          1. Types By Value
        2. Live attenuated vaccines
          1. By Value
        3. Inactivated vaccines
          1. By Value
        4. Sub-Unit viral vaccines
          1. By Value
      2. By Consumer groups
        1. Introduction
          1. Consumer groups By Value
        2. Pediatric
          1. By Value
        3. Adults
          1. By Value
      3. By Disease Indication
        1. Introduction
          1. Disease Indication By Value
        2. Cancer
          1. By Value
        3. Influenza
          1. By Value
        4. Human Papilloma Virus
          1. By Value
        5. Rota Virus
          1. By Value
        6. Poliomyelitis
          1. By Value
        7. Hepatitis
          1. By Value
        8. Others
          1. By Value
      4. By Route of Administration
        1. Introduction
          1. By Route of Administration By Value
        2. Parenteral
          1. By Value
        3. Oral
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Viral Vaccines Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. CureVac SE
    2. Pfizer Inc.
    3. Moderna, Inc
    4. Johnson & Johnson Services, Inc.
    5. AstraZeneca
    6. Dynavax Technologies
    7. Zydus Group
    8. Biological E Limited.
    9. Panacea Biotec Limited
    10. CSL
    11. Serum Institute of India Pvt. Ltd. 
    12. Bharat Biotech.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Market Overview The global animal vaccine market size was worth USD 9,588 million in 2021. It is expected to grow at a CAGR of 5.6% by 2030 to reach USD 15,567 million during the forecast period (2022–2030).  Animal vaccination is immuni
Buy Now
Global Report
Vaccines Market Size The global vaccines market size was valued at USD 67.58 billion in 2024 and is projected to grow from USD 65.83 billion in 2025 to USD 113.70 billion by 2033, exhibiting a CAGR of 7.07% during the forecast period (2025-2033). T
Buy Now
Global Report
The global veterinary vaccines market size was valued at USD 10.7 billion in 2022. It is projected to reach USD 19.7 billion by 2031, growing at a CAGR of 6.94% during the forecast period (2023–2031). Due to the increasing complexity and high
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.